Education
About Us
Working with TipRanks
Follow Us
Clinuvel Pharmaceuticals Limited (AU:CUV)
ASX:CUV
RESEARCH TOOLSreports
CUV Stock Chart & Stats
Day’s Range― - ―
52-Week RangeAU$9.76 - AU$17.71
Previous CloseN/A
Volume193.84K
Average Volume (3M)151.24K
Market Cap
$543.84M
Enterprise ValueAU$597.55M
Total Cash (Recent Filing)AU$9.93M
Total Debt (Recent Filing)AU$0.00
Price to Earnings (P/E)14.0
Beta0.36
Next Earnings
Sep 02, 2025EPS Estimate
0.38Last Dividend Ex-Date
Sep 05, 2024Dividend Yield0.48%
Share Statistics
EPS (TTM)0.77
Shares Outstanding50,123,630
10 Day Avg. Volume158,725
30 Day Avg. Volume151,240
Financial Highlights & Ratios
PEG Ratio0.51
Price to Book (P/B)N/A
Price to Sales (P/S)15.82
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$30.40Price Target Upside180.15% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
---
Clinuvel Pharmaceuticals Limited News
PremiumCompany Announcements
Clinuvel Pharmaceuticals Ceases 19,000 Performance Rights
PremiumCompany Announcements
CLINUVEL PHARMACEUTICALS Issues New Shares to Bolster Market Position
PremiumCompany Announcements
Clinuvel Pharmaceuticals Issues Shares Under Incentive Program
PremiumCompany Announcements
JPMorgan Reduces Stake in Clinuvel Pharmaceuticals
PremiumCompany Announcements
Clinuvel Pharmaceuticals Announces On-Market Share Buy-Back
PremiumCompany Announcements
CLINUVEL Pharmaceuticals Renews Share Buy-Back Program
PremiumCompany Announcements
Clinuvel Pharmaceuticals Completes Strategic Buy-Back---
Options Prices
Currently, No data available
---
Ownership Overview
0.03% Insiders
2.74%
Mutual Funds
― Other Institutional Investors
95.66% Public Companies and
Individual Investors
CUV FAQ
What was Clinuvel Pharmaceuticals Limited’s price range in the past 12 months?
Clinuvel Pharmaceuticals Limited lowest share price was AU$9.76 and its highest was AU$17.71 in the past 12 months.
What is Clinuvel Pharmaceuticals Limited’s market cap?
Clinuvel Pharmaceuticals Limited’s market cap is $543.84M.
When is Clinuvel Pharmaceuticals Limited’s upcoming earnings report date?
Clinuvel Pharmaceuticals Limited’s upcoming earnings report date is Sep 02, 2025 which is in 132 days.
How were Clinuvel Pharmaceuticals Limited’s earnings last quarter?
Clinuvel Pharmaceuticals Limited released its earnings results on Feb 26, 2025. The company reported AU$0.28 earnings per share for the quarter, beating the consensus estimate of AU$0.217 by AU$0.063.
Is Clinuvel Pharmaceuticals Limited overvalued?
According to Wall Street analysts Clinuvel Pharmaceuticals Limited’s price is currently Undervalued.
Does Clinuvel Pharmaceuticals Limited pay dividends?
Clinuvel Pharmaceuticals Limited pays a Annually dividend of AU$0.05 which represents an annual dividend yield of 0.48%. See more information on Clinuvel Pharmaceuticals Limited dividends here
What is Clinuvel Pharmaceuticals Limited’s EPS estimate?
Clinuvel Pharmaceuticals Limited’s EPS estimate is 0.38.
How many shares outstanding does Clinuvel Pharmaceuticals Limited have?
Clinuvel Pharmaceuticals Limited has 50,123,630 shares outstanding.
What happened to Clinuvel Pharmaceuticals Limited’s price movement after its last earnings report?
Clinuvel Pharmaceuticals Limited reported an EPS of AU$0.28 in its last earnings report, beating expectations of AU$0.217. Following the earnings report the stock price went up 2.89%.
Which hedge fund is a major shareholder of Clinuvel Pharmaceuticals Limited?
Currently, no hedge funds are holding shares in AU:CUV
---
Clinuvel Pharmaceuticals Limited Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$30.40 (180.15% Upside)
$30.40 (180.15% Upside)
Blogger Sentiment
Bullish
AU:CUV Sentiment 90%
Sector Average 70%
Sector Average 70%
News Sentiment
Neutral
Bullish news 50%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-29.53%
12-Months-Change
Fundamentals
Return on Equity
19.93%
Trailing 12-Months
Asset Growth
1.25%
Trailing 12-Months
Company Description
Clinuvel Pharmaceuticals Limited
Clinuvel Pharmaceuticals Limited, a biopharmaceutical company, focuses on developing and commercializing treatments for patients with genetic, metabolic, and life-threatening disorders in Australia, Europe, the United States, Switzerland, and internationally. Its lead drug candidate is SCENESSE, a systemic photoprotective drug for the prevention of phototoxicity in adult patients with erythropoietic protoporphyria (EPP). The company's pipeline products include CUV9900, an alpha-melanocyte stimulating hormone analogue; Parvysmelanotide (VLRX001), which provoke increased and prolonged cellular activity; and PRÉNUMBRA, a liquid injectable formulation of afamelanotide. Clinuvel Pharmaceuticals Limited has a collaboration agreement with HK Winhealth Pharma Group Co. Limited t to treat EPP patients with SCENESSE under a named patient program in the People's Republic of China. The company was founded in 1987 and is headquartered in Melbourne, Australia.
---
CUV Company Deck
---
CUV Earnings Call
Q2 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call highlighted strong financial performance with significant revenue growth and operational successes, such as expansion in treatment networks and ongoing development in the vitiligo program. However, rising expenses and challenges in drug development and regulatory approvals present some concerns. Despite these challenges, the company remains optimistic about future growth and market recognition.Read More>---
CUV Stock 12 Month Forecast
Average Price Target
AU$30.40
▲(180.15% Upside)
Technical Analysis
Opthea Limited
―
CSL
―
Immutep Ltd
―
Medical Developments International Limited
―
Recce Pharmaceuticals Ltd.
―
Best Analysts Covering CUV
1 Year
1 Year Success Rate
0/3 ratings generated profit
1 Year Average Return
-19.83%
reiterated a buy rating 6 months ago
Copying Sarah Mann's trades and holding each position for 1 Year would result in 0.00% of your transactions generating a profit, with an average return of -19.83% per trade.
---